Overview

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

Status:
Completed

Trial end date:
2006-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the blood pressure lowering effects of the combination of aliskiren 300 mg and HCTZ 25 mg in obese patients with essential hypertension inadequately treated with HCTZ 25 mg, compared to irbesartan or amlodipine with HCTZ or HCTZ alone.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Amlodipine
Irbesartan